Hey guys, welcome back to Skin Anarchy. This is a very, very special episode. I'm welcoming back a very dear friend of mine,

and also someone I truly admire for her work in the scientific space, in the skin health space. She is truly a genius.

And this brand is very special to me because they were one of our first big science forward brands that we hosted on Skin Anarchy.

So to welcome them back, it's truly like a full circle moment for me.

So without further ado, please welcome back. The founder of Droplet, Mothvi. Welcome, Madvi. I'm so excited to host to you again. Thank you. I'm so excited to be here. I'm really excited to chat about what we've been building. And so good to see you again, Ecta. Yeah, no, it's so good. I'm just so excited about what you're continuing to do in the space. I mean, I know when we first spoke about Droplet, and I'm going to have you, like, walk our listeners through the whole journey again, but just to like preface, like, when you first told me about Droplet, I was like blown away. Like, And I still am. You know, like, to this day, I'm like, this is so revolutionary,

especially now, I think, more than ever, when consumers care so much about, like, are you getting the most of your products? Is it going to the layers it needs to go into? So all of that stuff coming together and, like, understanding your science is so, I don't know, it's just such a fresh, like a breath of fresh air, you know, in the industry. So with me ranting,

I want to now give you the mic and have you tell us, you know, tell us about Dropplet for everybody that might have missed the first episode. You know, where did it start? So Droplett initially

started as a medical technology. So my background is in pharmaceutical development. I worked in designing drugs for pediatric

patients. And along the way, I worked in pediatric cardiomyopathy, so heart disease and children.

And along the way, I learned about this rare disease called epidermalysis bolosa, which anyone in the

dermatology field is unfortunately very familiar with.

And it's basically one where patients are missing a gene that codes for a connective

protein that connects your skin to the tissue below it.

And when that gene is missing, the skin doesn't properly adhere.

So as a drug designer, the way I've been trained to think about it is you target the

protein, like you find a therapeutic, and then, you know, you're done. The disease is cured. And

unfortunately for skin, for many skin conditions, that's just not true because delivery is actually

the big challenge. So in this case, the treatment is a gene therapy, which is, you know,

like not to minimize the field, but it's doable, right?

But the issue in terms of actual treatment is getting the gene to where it needs to go in the tissue.

So that's how I got involved in the delivery problem, and that was the entire basis for droplet technology.

So what we've designed is this little handheld device

...